OpenEvidence raises $200M at a $6B valuation

Clinical AI startup OpenEvidence plans to raise $200 million at a $6 billion valuation, only three months after a $210 million round at $3.5 billion. The brief cites GV as lead, alongside Sequoia, Kleiner Perkins, Blackstone, Thrive, Coatue, Bond and Craft, with reported usage at ~15 million clinical consultations per month. 

Healthcare AI has mostly swung between hype and HIPAA headaches. What stands out here isn’t just the price tag; it’s distribution and data provenance. OpenEvidence leans into vetted medical literature (JAMA, NEJM) instead of web exhaust—catnip for hospital compliance teams. If that 15M-consultations stat holds, the unit-economics conversation shifts from “can this be used?” to “how broadly can this be rolled out?”

Specialized, regulated-domain AI is where check sizes have been inflating this fall, as general-purpose LLM competition gets brutal and margins compress. A rapid step-up from $3.5B to $6B in a single quarter signals that institutions want workflow-grade models with defensible corpuses, not just shiny demos.

Big, fast follow-on at a premium valuation says the quiet part loud: medical AI with clean inputs and clinical guardrails is where late-stage capital still wants to play.